A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation

Trial Profile

A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 24 Jul 2013

At a glance

  • Drugs Tivozanib (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Jun 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 08 Apr 2013 Planned initiation date changed from 1 Feb 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
    • 07 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top